NDA 216059 · Loxo Oncol
Jaypirca
Pirtobrutinib · Oral · Kinase Inhibitor
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Jan 27, 2023: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jan 27, 2023
Approved uses
4
Original approval plus efficacy supplements
Registered trials
81
10 Phase 3, 36 recruiting
FAERS reports
980
680 serious, 232 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 2, 2026.
JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ) This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. ( 1.2 ) Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. ( 1.3 ) 1.1 Mantle Cell Lymphoma JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p...
Mechanism: Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor...
Therapeutic areas: Oncology · Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2026 Supplement 6 · Efficacy OrphanLabelLetter
- Dec 2, 2025 Supplement 5 · Efficacy OrphanLabelLetter
- Dec 1, 2023 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- Jan 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
- JAYPIRCA · PIRTOBRUTINIB 50MG · TABLET, ORAL · Prescription
- JAYPIRCA · PIRTOBRUTINIB 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pirtobrutinib" as an intervention, any sponsor and status, largest first.
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06876649 · 787 participants (planned) · Start May 20, 2025 · Primary completion May 2030
Drug: Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
Sites: Jacksonville, Florida; Miami, Florida; Sarasota, Florida · 38 sites in all
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Pivotal-lookingRecruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT05254743 · 737 participants (planned) · Start Jul 22, 2022 · Primary completion Oct 2027
Drug: Pirtobrutinib; Ibrutinib · For: Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell and 1 more
Sites: Anaheim, California; Cerritos, California; Palo Alto, California · 143 sites in all
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLPivotal-lookingRecruiting
Nurix Therapeutics, Inc.Industry
NCT07516093 · 620 participants (planned) · Start Aug 3, 2026 · Primary completion Oct 2029
Drug: NX-5948; Pirtobrutinib · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Macon, Georgia; Fort Wayne, Indiana; Indianapolis, Indiana · 6 sites in all
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Pivotal-lookingActive, not recruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT04965493 · 600 participants (planned) · Start Sep 20, 2021 · Primary completion Oct 2026
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Chandler, Arizona; Phoenix, Arizona; Orange, California · 176 sites in all
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06973187 · 500 participants (planned) · Start Sep 4, 2025 · Primary completion Apr 17, 2028
Drug: Tacabrutideg; Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Irvine, California · 217 sites in all
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Pivotal-lookingActive, not recruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT04662255 · 500 participants (planned) · Start Apr 8, 2021 · Primary completion Nov 2027
Drug: Pirtobrutinib; Ibrutinib and 2 more · For: Lymphoma, Mantle-Cell
Sites: Anchorage, Alaska; Phoenix, Arizona; Los Angeles, California · 189 sites in all
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLPivotal-lookingRecruiting
Newave Pharmaceutical IncIndustry
NCT07342478 · 306 participants (planned) · Start Apr 23, 2026 · Primary completion Oct 30, 2029
Drug: Rocbrutinib; Pirtobrutinib · For: CLL / SLL; CLL (Chronic Lymphocytic Leukemia); CLL, Refractory and 5 more
Sites: Skokie, Illinois; Bethesda, Maryland; Las Vegas, Nevada · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death120
- malignant neoplasm progression88
- pneumonia74
- off label use70
- disease progression64
- splenomegaly44
- chronic lymphocytic leukaemia41
- anaemia37
- drug ineffective35
- pancytopenia35
- lymphadenopathy33
- white blood cell count increased31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 17 |
| 2023 | 117 |
| 2024 | 173 |
| 2025 | 286 |
| 2026 | 387 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jaypirca (Pirtobrutinib)
2024 spending
$201M
Beneficiaries
1,795
9,927 claims
Per beneficiary
$111,734
$355.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $49,251,883 |
| 2024 | $200,562,025 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Sharman JP, Munir T, Grosicki S, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, et al. · Lancet 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR, Woyach JA, Brown JR, et al. · N Engl J Med 2023 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Woyach JA, Qiu L, Grosicki S, et al. · J Clin Oncol 2026 · Randomized Controlled Trial, Comparative Study
- BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jurczak W, Kwiatek M, Czyz J, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Al-Sawaf O, Jen MH, Hess LM, et al. · Haematologica 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.